Introduction
============

The sustained-release intravitreal (IV) 0.7 mg dexamethasone (DEX) implant (Ozurdex^®^, Allergan Pharmaceuticals, Irvine, CA, USA) is approved in Europe for the treatment of macular edema related to the following diseases: diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion, and non-infectious uveitis.[@b1-dddt-11-2359]

DEX is one of the 3 most commonly used intraocular corticosteroids together with triamcinolone acetonide (TA) and fluocinolone acetonide. However, compared with these, DEX differs in its pharmacokinetics and pharmacodynamics properties due to certain biological effectiveness: different glucocorticoid receptor binding affinity (DEX \> fluocinolone \> triamcinolone) and different anti-inflammatory activities (DEX = fluocinolone and is 5 times more active than triamcinolone).[@b1-dddt-11-2359],[@b2-dddt-11-2359] The advantage of a DEX implant, containing micronized, preservative-free DEX 0.7 mg in a biodegradable copolymer of polylactic-co-glycolic acid (which eventually breaks down into carbon dioxide and water), is the release of the active ingredient within the vitreous chamber for up to 6 months after an IV injection. All these aforementioned features allow reduction in the frequency of injections with benefit in terms of hospital and patient resource saving, including diminished complications related to injection procedure (eg, retinal detachment, endophthalmitis, lens iatrogenic injury, etc). However, in real life it has been shown that a shorter-interval re-treatment is required because of the loss of the drug's effectiveness before 6 months, with a reported range varying from 4 to 5.9 months.[@b3-dddt-11-2359],[@b4-dddt-11-2359] Another relevant pharmacological aspect, as demonstrated by experimental studies, is the reduction of IV drugs half-life in vitrectomized eyes compared with non-vitrectomized ones, making their use ineffective.[@b5-dddt-11-2359] On the contrary, DEX implant has the advantage of maintaining the same half-life and, therefore, the same pharmacological properties in both vitrectomized and non-vitrectomized eyes.[@b6-dddt-11-2359]--[@b8-dddt-11-2359]

Regarding complications related to the use of DEX implant, pivotal studies and real-life studies have confirmed a good safety profile with only a few complications: cataract progression in the range from 29.8%[@b9-dddt-11-2359] to 67.9%,[@b10-dddt-11-2359] closely related to the number of implants received, and an increase of intraocular pressure (IOP) \>10 mmHg from baseline reported in a range of 15.4%[@b9-dddt-11-2359] and 27.7%[@b10-dddt-11-2359] of cases. There are several reviews collecting literature data about the approved use of sustained-release DEX implants. However, there are various ocular pathologies with inflammatory etiopathogeneses associated with macular edema, such as: neovascular age-related macular degeneration (nAMD); Irvine--Gass syndrome (IGS); vasoproliferative retinal tumors (VPRTs); retinal telangiectasia and Coats' disease; radiation maculopathy; retinitis pigmentosa; macular edema secondary to scleral buckling and pars plana vitrectomy (PPV), all of which have been treated by DEX implant.

The aim of this review was to provide a systematic collection of all of the diseases that benefit from the use of the sustained-release DEX implant alone or in combination with concomitant therapies in order to provide a valuable therapy option for these diseases in clinical practice.

Methods
=======

MEDLINE databases for the period 2009 to September 2016 were searched by using the medical subject heading "Dexamethasone intravitreal implant/Ozurdex" and the keywords "macular edema, age-related macular degeneration, Irvine--Gass, pseudophakic cystoid macular edema, post-operative macular edema, PPV, scleral buckling, retinitis pigmentosa, prostaglandin, radiation macular edema, telangiectasia." Studies were limited to the English language. Because randomized controlled trials on these topics were lacking, all studies (retrospective and prospective, comparative and non-comparative, randomized and nonrandomized, single center and multicenter, and case reports) were analyzed. Aims, and anatomical and functional outcomes, and complications after DEX implant were analyzed.

nAMD
====

Approved first-line therapy for nAMD is based on the use of anti-vascular endothelial grow factor (VEGF) IV injections such as pegaptanib, ranibizumab, and aflibercept. However, there are patients who have a non-complete response to anti-VEGF injections as well as patients who, after an optimal functional and anatomical response, develop tachyphylaxis.[@b11-dddt-11-2359] The explanation for this incomplete response lies in the multifactorial pathogenesis of AMD, which involves VEGF, inflammation, and oxidative stress, as seen in histological studies performed on neovascular membranes after their surgical excision. Neovascular membrane growth in the subretinal space is stimulated by activated macrophages (and other inflammatory cells secreting cytokines) and enzymes that can damage the Bruch's membrane.[@b12-dddt-11-2359] Therefore, inflammation is another potential target of nAMD treatment that could be counteracted by the use of corticosteroids.

Combination therapy consisting of anti-VEGF therapy and a corticosteroid relies on the use of drugs with different mechanisms of action, and could allow the reduction of anti-VEGF IV injection frequency and therefore, improve long-term efficacy and safety while reducing scarring results.[@b13-dddt-11-2359]--[@b16-dddt-11-2359] Using combination therapies to treat nAMD dates back to photodynamic therapy (PDT), when it was associated with the IV TA injection.[@b17-dddt-11-2359],[@b18-dddt-11-2359] However, side effects due to IV TA, such as cataract progression and increased IOP, sometimes resistant to medical therapy, halted these procedures despite anatomical and functional benefits.[@b19-dddt-11-2359] Cataract surgery has been reported in around 45.2% of eyes that underwent triamcinolone injection,[@b19-dddt-11-2359] and ocular hypertension (IOP \>21 mmHg) in around 44.6% of eyes, with IOP-lowering surgery required in 0.3% of eyes.[@b20-dddt-11-2359]

The LuceDex study[@b21-dddt-11-2359] was the first study using the IV DEX injections (500 mg in 0.05 mL), followed by IV ranibizumab (4 monthly injections of 0.5 mg in 0.05 mL) that was compared with IV ranibizumab monotherapy (Group 2; total 37 patients). After 4 consecutive months, in both groups, ranibizumab pro re nata treatment was administered if signs of lesion activity were present. The results of this study showed a clear benefit for combination therapy, with reduction in the dimension of the choroidal neovascular membrane, detected by fluorescein angiography, improvement in visual acuity, and reduced treatment frequency. Central macular thickness (CMT) and volume reductions were also observed, although these changes were not statistically significant.

After the approval of the DEX implant, several authors evaluated its efficacy in nAMD[@b22-dddt-11-2359]--[@b25-dddt-11-2359] ([Table 1](#t1-dddt-11-2359){ref-type="table"}). Compared with ranibizumab monotherapy, studies showed no long-term improvement of best corrected visual acuity (BCVA) and reduction of CMT;[@b22-dddt-11-2359]--[@b25-dddt-11-2359] however, DEX implant in some cases allowed a reduced number of anti-VEGF injections.[@b23-dddt-11-2359],[@b24-dddt-11-2359]

One study[@b24-dddt-11-2359] reported an incidence of cataract surgery of 9% in ranibizumab-treated eyes and 33% in eyes receiving 2 DEX implants. The incidence of ocular hypertension ranged from 15% to 42%,[@b22-dddt-11-2359]--[@b25-dddt-11-2359] all treated with topical hypotonizing therapy.

IGS
===

The most likely physiopathological hypothesis for IGS is an inflammatory response instigated by the inflammatory mediators released during and after surgical procedures, causing alterations to the blood--retinal barrier. Many risk factors have been identified, such as posterior capsule rupture and vitreous loss, as well as the use of iris retractors, the presence of an epiretinal membrane, a vein occlusion, a history of uveitis or diabetes and the use of prostaglandin eye drops.[@b26-dddt-11-2359]

First-line treatment for IGS involves the use of different therapies: topical nonsteroidal anti-inflammatory drugs (NSAIDs), oral acetazolamide, and topical corticosteroids. In patients resistant to such treatments, the following off-label treatment options have been tried:[@b26-dddt-11-2359]--[@b32-dddt-11-2359] IV anti-VEGFSubcutaneous interferon α2a injectionsIV infliximab (anti-tumor necrosis factor-α)Intra-, retro-, and peribulbar corticosteroidsPPV

Several authors have evaluated the efficacy of DEX implant for chronic IGS[@b33-dddt-11-2359]--[@b45-dddt-11-2359] ([Table 2](#t2-dddt-11-2359){ref-type="table"}).

Most of the studies had a 6-month follow-up; they showed a significant improvement in BCVA and a significant reduction in CMT with 1 DEX implant. Two prospective studies[@b38-dddt-11-2359],[@b43-dddt-11-2359] of DEX compared with IVTA showed similar functional effects and anatomical effects: one found a lower incidence of ocular hypertension in the DEX group (at 6 months 0% vs 20%, *P*=0.044).

A retrospective long-term study[@b44-dddt-11-2359] that included 58 cases of IGS in a total of 100 eyes found that efficacy was maintained at 24 months, after a mean number of 1.77 DEX implants in the first year and 1.70 in the second year. At 24 months, an IOP \>25 mmHg was found in 6.2% of the patients, all treated with hypotensive eye drops and not requiring filtering surgery.[@b44-dddt-11-2359]

VPRTs
=====

Several approaches have been used to treat VPRTs, including cryotherapy, laser photocoagulation, PDT, IV anti-VEGF, plaque brachytherapy, and PPV.[@b45-dddt-11-2359]--[@b47-dddt-11-2359]

VPRTs treated by DEX and PDT were reported in 3 cases[@b48-dddt-11-2359] ([Table 3](#t3-dddt-11-2359){ref-type="table"}). Total involution of the tumor was reported within 2 months and regression of exudates continued for several months, leaving fibrotic scar tissue in the inferior half of the retina.[@b48-dddt-11-2359]

Retinal telangiectasia and Coats' disease
=========================================

Retinal telangiectasia
----------------------

Yannuzzi et al[@b49-dddt-11-2359] have recently classified different forms of idiopathic macular telangiectasia: aneurismal telangiectasia, idiopathic perifoveal telangiectasia, and occlusive telangiectasia. Although several approaches have been suggested for the treatment of idiopathic macular telangiectasia (including laser photocoagulation,[@b50-dddt-11-2359] PDT,[@b51-dddt-11-2359] IV anti-VEGF,[@b52-dddt-11-2359] PPV[@b53-dddt-11-2359]), no treatment has yet been shown to provide a consistent effect on visual acuity. Also, corticosteroids have been used to treat these vascular pathologies due to their biological effect[@b54-dddt-11-2359] and DEX implant can be assumed to be an useful therapeutic device,[@b55-dddt-11-2359],[@b56-dddt-11-2359] which can also be administered in pediatric patients[@b57-dddt-11-2359] ([Table 4](#t4-dddt-11-2359){ref-type="table"}).

In these cases, with a longer follow-up, multiple DEX implants were performed, at each time successfully (leading to BCVA improvement and CMT reduction).[@b56-dddt-11-2359]--[@b58-dddt-11-2359]

Coats' disease
--------------

In Coats' disease, ablative therapy by laser photocoagulation and cryotherapy is the gold standard of treatment[@b57-dddt-11-2359] with photocoagulation preferred over cryotherapy in cases with little or no subretinal fluid.[@b57-dddt-11-2359] IV therapies such as anti-VEGF and steroids could be used to improve anatomic and visual outcomes,[@b58-dddt-11-2359],[@b59-dddt-11-2359] in particular, in combination with ablative therapies. IV corticosteroids, including DEX implant[@b60-dddt-11-2359]--[@b62-dddt-11-2359] have been used to reduce intraocular inflammation, tighten capillary walls, and suppress cell proliferation, also having anti-VEGF properties,[@b58-dddt-11-2359] ([Table 5](#t5-dddt-11-2359){ref-type="table"}).

In one case, DEX implant led to a resolution of the exudative retinal detachment allowing laser photocoagulation of telangiectatic vessels.[@b63-dddt-11-2359] In other cases, final BCVA was influenced by subfoveal fibrosis, present at the time of the treatment[@b58-dddt-11-2359] or existing over a long-term.[@b60-dddt-11-2359]

Radiation maculopathy
=====================

Several treatments have been proposed for radiation maculopathy, including laser photocoagulation, PDT, periocular injection of TA, IV anti-VEGF and, most recently, DEX implant ([Table 6](#t6-dddt-11-2359){ref-type="table"}).[@b63-dddt-11-2359]--[@b68-dddt-11-2359] All of these studies demonstrated a significant anatomical benefit with DEX implant in cases of recalcitrant radiation macular edema, with significant changes in visual acuity in most of the cases. Two comparative studies[@b65-dddt-11-2359],[@b67-dddt-11-2359] comparing DEX implant with anti-VEGF therapy, found no difference in outcomes, and a reduction in the number of injections in DEX-treated eyes.[@b65-dddt-11-2359]

IOP increased in some eyes,[@b63-dddt-11-2359],[@b64-dddt-11-2359],[@b66-dddt-11-2359] all successfully treated by topical hypotonizing therapy. Cataract development in these cases[@b64-dddt-11-2359]--[@b66-dddt-11-2359] could be caused by DEX or the radiation therapy.

Retinitis pigmentosa
====================

The exact pathogenesis of macular edema, whether it is related to chronic and low-grade inflammatory process[@b69-dddt-11-2359] or to autoimmune process as antiretinal antibodies[@b70-dddt-11-2359] or to the failure of the retinal pigment epithelium pumping mechanism, is unknown as yet.[@b71-dddt-11-2359] Treatments attempted include topical and systemic administration of CAI,[@b71-dddt-11-2359] NSAIDs, retinal laser photocoagulation, vitrectomy surgery,[@b72-dddt-11-2359] and IV anti-VEGF.[@b73-dddt-11-2359] Also, IV corticosteroids injections have been performed as these drugs may modulate the inflammatory mediators and the autoimmune process.[@b74-dddt-11-2359]--[@b76-dddt-11-2359]

The studies reporting on the use of DEX in macular edema related to retinitis pigmentosa consist of case report studies, which include only a few eyes ([Table 7](#t7-dddt-11-2359){ref-type="table"}).[@b77-dddt-11-2359]--[@b80-dddt-11-2359] Nevertheless, an anatomical and functional improvement has been shown, but a relapse of macular edema occurred before 6 months from the implant[@b77-dddt-11-2359] and an additional DEX was required in some cases.[@b77-dddt-11-2359],[@b78-dddt-11-2359] DEX implant proved to be safe with an IOP rise \>21 mmHg recorded in only one eye.[@b78-dddt-11-2359]

DEX implant in macular edema after retinal surgery
==================================================

DEX implant was used also in case of macular edema secondary to PPV for epiretinal membrane or macular hole or scleral buckling ([Table 8](#t8-dddt-11-2359){ref-type="table"}).[@b81-dddt-11-2359]--[@b85-dddt-11-2359] In all cases, an anatomical and functional improvement was shown, even though in 2 cases, multiple DEX implants were performed because of recurrent macular edema.[@b82-dddt-11-2359] Additionally, the use of DEX allowed resolution of severe choroidal inflammation detected in 1 case following scleral buckle surgery.[@b85-dddt-11-2359]

Conclusion
==========

The use of DEX implant for all of the aforementioned macular pathologies merits consideration, and the results reported can support the use of DEX implant on a case-by-case basis with the aim of improving patient outcomes in many macular pathologies.

In many of these cases, DEX implant allowed a reduction of CMT with an improvement of BCVA, even if, at long term, many eyes required retreatment because DEX implant started to lose its efficacy, sometimes at 3 months after the injection.

Many of these cases were refractory to previous treatments, and DEX implant was administered as the last treatment option. Consequently, the functional results provided may be influenced by the lateness of DEX implant use. Therefore, considering that many of the reported macular pathologies may be difficult to treat and that some of them are not especially uncommon, having an awareness of a new treatment option and its influence on the clinical course of the disease may represent a great assistance in clinical practice. Furthermore, the use of DEX remains the only solution in treating macular edema in vitrectomized eyes where the efficacy of other IV drug injections, such as anti-VEGF, is lost due to their pharmacokinetic properties.

DEX implant-related adverse events in this expanding-use scenario are consistent with those previously documented for the DEX treatment of diabetic macular edema, uveitis, and retinal vein occlusion.[@b10-dddt-11-2359],[@b86-dddt-11-2359],[@b87-dddt-11-2359] In the cases that we analyzed, cataract was reported in up to 33% of the eyes after 2 DEX implants,[@b24-dddt-11-2359] and the occurrence of ocular hypertension (IOP ≥25 mmHg) from 6%[@b38-dddt-11-2359] to 31%,[@b32-dddt-11-2359] all treated with topical therapy.

In conclusion, DEX implant may allow less frequent anti-VEGF treatment[@b24-dddt-11-2359],[@b65-dddt-11-2359] and therefore, the advantages for the patient are clear: the need to undergo stressful treatment is removed while ocular and systemic adverse effects are reduced.
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###### 

Published studies on the use of DEX implant for age-related macular degeneration

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                Study design                                        No of eyes            Previous treatment                  Treatment                                           Follow-up                          Retreatment                  BCVA                                                      CMT                                                            Complications
  ---------------------------------------- --------------------------------------------------- --------------------- ----------------------------------- --------------------------------------------------- ---------------------------------- ---------------------------- --------------------------------------------------------- -------------------------------------------------------------- ------------------------
  Calvo et al[@b22-dddt-11-2359]           Retrospective                                       7 refractory          3 anti-VEGF                         1 DEX + ranibizumab monthly                         6 months                           2 DEX (28.5%)                From 0.53±0.13 logMAR to 3 months: 0.45±0.3 (*P*=0.23)\   From 273.14±50.94 μm to 3 months: 241.5±36.6 μm; (*P*=0.04)\   3 ocular hypertension\
                                                                                                                                                                                                                                                                             6 months: 0.52±0.2 (*P*=0.23)                             6 months: 260.71±58.51 μm (*P*=0.40)                           (42.8%)\
                                                                                                                                                                                                                                                                                                                                                                                                      (27--32 mmHg)

  Kuppermann et al [@b23-dddt-11-2359]     Prospective multicenter randomized                  243                   115 naïve:                          58 DEX + ranibizumab vs 57 sham + ranibizumab PRN   6 months                           3.15 DEX + ranibizumab PRN   Naïve\                                                    Naïve\                                                         DEX\
                                                                                                                                                                                                                                                                             Change from baseline:\                                    Change from baseline: DEX:\                                    18.2%\
                                                                                                                                                                                                                                                                             DEX: +0.3 to +2.7 L Sham:\                                −12.61±96.4 μm Sham:\                                          IOP ≥25 mmHg
                                                                                                                                                                                                                                                                             −0.5 to +2.6 L                                            −34.70±106.6 μm\                                               
                                                                                                                                                                                                                                                                                                                                       (*P*\<0.05)                                                    

  128 prev treatment                       65 DEX + ranibizumab vs 63 sham + ranibizumab PRN                         3.37 sham + ranibizumab             Prev treatment\                                     Prev treatment\                    Sham 5.1%\                                                                                                                                            
                                                                                                                                                         Change from baseline:\                              Change from baseline:\             IOP ≥25 mmHg\                                                                                                                                         
                                                                                                                                                         DEX: +0.4 to +2.4 L\                                DEX:−1.74±54.4 μm\                 (*P*=0.002)                                                                                                                                           
                                                                                                                                                         Sham: −0.3 to 2.6 L                                 Sham:+6.84±84.9 μm (*P*=ns)                                                                                                                                                              

  Rezar-Dreindl et al[@b24-dddt-11-2359]   Prospective randomized                              40                    5.6±3.4 ranibizumab                 20 ranibizumab                                      12 months                          7.95 ranibizumab\            From 62 to 68 L\                                          From 485 μm to 6 months: 426 μm\                               9% cataract surgery\
                                                                                                                                                                                                                                                *P*=0.042                    (*P*=0.2)                                                 12 months: 453 μm\                                             0% IOP \>30 mmHg\
                                                                                                                                                                                                                                                                                                                                       (*P*=0.38)                                                     \
                                                                                                                                                                                                                                                                                                                                                                                                      33% cataract surgery

  6.7±4.4 ranibizumab                      20 ranibizumab + DEX                                                      5.5 ranibizumab + 2 DEX (18 eyes)   68 to 71 L                                          From 439 μm to 6 months: 375 μm\   15% IOP \>30 mmHg                                                                                                                                     
                                                                                                                                                                                                             12 months: 368 μm                                                                                                                                                                        

  Chaudhary et al[@b25-dddt-11-2359]       Prospective multicenter randomized                  10                    NR                                  5 ranibizumab                                       6 months                           6.2±2.3                      Change from baseline:\                                    Change from baseline:\                                         1 IOP \>30 mmHg
                                                                                                                                                                                                                                                                             10.8±13.2 L\                                              31.7%±17.5% to 13.3%±27.0% (*P*=0.236)                         
                                                                                                                                                                                                                                                                             3.0±10.5 L\                                                                                                              
                                                                                                                                                                                                                                                                             (*P*=0.331)                                                                                                              

  5 ranibizumab + DEX                                                                          5.8±1.8 (*P*=0.766)                                                                                                                                                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BCVA, best corrected visual acuity; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; Naïve, previously untreated; NR, not reported; ns, not significant; prev treatment, previously treated; PRN, pro re nata; VEGF, vascular endothelial growth factor.

###### 

Published studies on the use of DEX implant for Irvine--Gass syndrome

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                 Study design                              No of eyes                               Previous treatment                                  Treatment                                   Follow-up    Retreatment                                                                           BCVA                                                       CMT                                                              Complications
  --------------------------------------------------------- ----------------------------------------- ---------------------------------------- --------------------------------------------------- ------------------------------------------- ------------ ------------------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------------- ----------------------------
  Williams et al[@b33-dddt-11-2359]                         Prospective multicenter randomized        41 uveitis + IGS (27)                    Laser Medical therapy                               DEX 0.7 mg or DEX 0.35 mg observation       6 months     NR                                                                                    53.8% improvement ≥10 L after 3 months (*P*=0.029)\        NR                                                               31% IOP \>25 mmHg (0.7 mg)
                                                                                                                                                                                                                                                                                                                                                  41.7% improvement ≥10 L after 3 months (*P*=0.117)\                                                                         
                                                                                                                                                                                                                                                                                                                                                  14.3% improvement ≥10 L after 3 months                                                                                      

  Meyer and Schönfeld[@b34-dddt-11-2359]                    Case report                               1                                        3 IVT 0.4 mg dexamethasone                          1 DEX                                       4 months     NR                                                                                    From 0.30 to 0.8 (for at least 3 months)                   From 393 μm to 212 μm (for at least 3 months)                    NR

  Dutra Medeiros et al[@b35-dddt-11-2359]                   Retrospective                             9                                        CAIs\                                               1 DEX                                       6 months     NR                                                                                    From 0.62±0.15 logMAR to 1 month: 0.47±0.21 (*P*=0.008)\   From 542.22±134.78 μm to 1 month: 350.88±98.71 μm (*P*=0.001)\   NR
                                                                                                                                               Topical NSAIDs\                                                                                                                                                                                    3 months: 0.37±0.24 (*P*=0.001)\                           3 months: 319.22±60.96 μm (*P*=0.002)\                           
                                                                                                                                               Corticosteroids\                                                                                                                                                                                   6 months: 0.37±0.26 (*P*=0.002)                            6 months: 398.33±127.89 μm (*P*=0.031)                           
                                                                                                                                               IVT anti-VEGF\                                                                                                                                                                                                                                                                                                                 
                                                                                                                                               IVT TA                                                                                                                                                                                                                                                                                                                         

  Brynskov et al[@b36-dddt-11-2359]                         Case report                               1                                        TA Sub-Tenon's 5 Ranibizumab IVT                    DEX                                         12           Second DEX (187 days later)                                                           First DEX: from 78\                                        First DEX: from 541 to 219 μm (after 83 days)\                   NR
                                                                                                                                                                                                                                                                                                                                                  ETDRS letters to 76\                                       Second DEX: from 436 to 229 μm (after 56 days)                   
                                                                                                                                                                                                                                                                                                                                                  Second DEX: from 76\                                                                                                        
                                                                                                                                                                                                                                                                                                                                                  ETDRS letters to 85                                                                                                         

  Fenicia et al[@b37-dddt-11-2359]                          Case report                               1 patient (2 eyes)                       RE: topical NSAIDs\                                 RE: DEX + Ranibizumab IVT (84 days later)   NR           RE: 1DEX +1 ranibizumab IVT (84 days later) +1 DEX (2 months later IVT ranibizumab)   RE: from 20/70 to 50 days 20/20                            −369 μm after 7 days                                             NR
                                                                                                                                               Oral indomethacin 3 peribulbar methylprednisolone                                                                                                                                                                                                                                                                              

  LE: topical NSAIDs                                        LE: DEX                                                                                                                                                                                                                                                                                                                                                                                                           

  Oral indomethacin                                                                                                                                                                                LE: from 20/40 to 80 days 20/20                                                                                                                                                                                                                                            

  Ranibizumab IVT                                                                                                                              2 DEX (5 months after)                                                                                                                                                                                                                                                                                                         

  Dang et al[@b38-dddt-11-2359]                             Prospective, nonrandomized, comparative   18                                       Topical steroids\                                   DEX                                         6                                                                                                  1 month: VAI 44%\                                          1 month: −175 μm (mean change), *P*=0.783 vs TA\                 DEX\
                                                                                                                                               Topical NSAIDs                                                                                                                                                                                     *P*=0.625 vs TA\                                           2 months: −145 μm (mean change), *P*=0.044 vs TA\                1 month: 6%\
                                                                                                                                                                                                                                                                                                                                                  2 months: VAI 39%\                                         3 months: −126 μm (mean change), *P*=0.049 vs TA                 IOP\>21 mmHg\
                                                                                                                                                                                                                                                                                                                                                  *P*=0.941 vs TA\                                                                                                            2 months: 6%\
                                                                                                                                                                                                                                                                                                                                                  3 months: VAI 39%\                                                                                                          IOP\>21 mmHg\
                                                                                                                                                                                                                                                                                                                                                  *P*=0.553 vs TA\                                                                                                            3 months: 6%\
                                                                                                                                                                                                                                                                                                                                                  6 months: VAI 33%\                                                                                                          IOP\>21 mmHg\
                                                                                                                                                                                                                                                                                                                                                  *P*=0.856 vs TA                                                                                                             6 months: 0%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                              IOP\>21 mmHg (*P*=0.044)

  NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                             6 months: −125 μm (mean change), *P*=0.812 vs TA                 

                                                                                                      25                                                                                           TA                                                       15 1 IVT TA\                                                                          1 month: VAI 52%\                                          1 month: −193 μm (mean change)\                                  TA\
                                                                                                                                                                                                                                                            9 2 IVT TA\                                                                           2 months: VAI 40%\                                         2 months: −95 μm (mean change)\                                  1 month: 12%\
                                                                                                                                                                                                                                                            1 3 IVT TA                                                                            3 months: VAI 48%\                                         3 months: −173 μm (mean change)\                                 IOP\>21 mmHg\
                                                                                                                                                                                                                                                                                                                                                  6 months: VAI 36%                                          6 months: −140 μm (mean change)                                  2 months: 12%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                              IOP\>21 mmHg\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                              3 months: 20%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                              IOP\>21 mmHg\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                              6 months: 20%\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                              IOP\>21 mmHg

  Furino et al[@b39-dddt-11-2359]                           Retrospective                             11                                       NR                                                  1 DEX                                       6.27±0.47    NR                                                                                    From 20/40 to 20/22\                                       From 462±100 μm to 276±8 μm\                                     IOP\>20 mmHg
                                                                                                                                                                                                                                                                                                                                                  (*P*\<0.0001)                                              (*P*\<0.0001)                                                    

  Al Zamil[@b40-dddt-11-2359]                               Retrospective                             11                                       Oral CAIs\                                          1 DEX                                       6            NR                                                                                    From 0.58±0.17\                                            From 513.8±134.9 μm to 1 month: 371.6±91.9\                      NR
                                                                                                                                               Topical NSAIDs\                                                                                                                                                                                    logMAR to 1 month: 0.37±0.16\                              (*P*=0.001)\                                                     
                                                                                                                                               Corticosteroids\                                                                                                                                                                                   logMAR (*P*=0.008)\                                        3 months: 302.6±50.9 μm\                                         
                                                                                                                                               IVT anti-VEGF\                                                                                                                                                                                     3 months: 0.20±0.13\                                       (*P*=0.002)\                                                     
                                                                                                                                               IVTA                                                                                                                                                                                               logMAR (*P*=0.001)\                                        6 months: 308.0±54.5 μm\                                         
                                                                                                                                                                                                                                                                                                                                                  6 months: 0.21±0.15\                                       (*P*=0.031)                                                      
                                                                                                                                                                                                                                                                                                                                                  logMAR (*P*=0.002)                                                                                                          

  Khurana et al[@b41-dddt-11-2359]                          Prospective case series                   6                                        Topical NSAIDs                                      1 DEX                                       NR                                                                                                 6 months: +14 L\                                           1 month: −100 μm\                                                
                                                                                                                                                                                                                                                                                                                                                  (*P*=0.03)                                                 (mean change)\                                                   
                                                                                                                                                                                                                                                                                                                                                                                                             (*P*\<0.01)\                                                     
                                                                                                                                                                                                                                                                                                                                                                                                             6 months: −72 μm\                                                
                                                                                                                                                                                                                                                                                                                                                                                                             (mean change)\                                                   
                                                                                                                                                                                                                                                                                                                                                                                                             (*P*=0.004)                                                      

  Ortega- Evangelico and Diago Sempere[@b42-dddt-11-2359]   Retrospective                             4                                        NR                                                  1 DEX                                       6                                                                                                  From 0.3 to 1 month: 0.575 logMAR (mean)\                  From 414 μm to 1 month: 330.25 μm\                               NR
                                                                                                                                                                                                                                                                                                                                                  3 months: 0.575\                                           (mean change)\                                                   
                                                                                                                                                                                                                                                                                                                                                  logMAR (mean)                                              3 months: 346.75 μm (mean change)                                

  Mylonas et al[@b43-dddt-11-2359]                          Prospective randomized                    29                                       NR                                                  14 IVTA                                     6            19 second IVTA                                                                        From 63±13 L to 1 month: 73±11 L\                          From 516±121 μm to 1 month: 355±59 μm\                           
                                                                                                                                                                                                                                                                                                                                                  (*P*=0.001)\                                               (*P*=0.003)\                                                     
                                                                                                                                                                                                                                                                                                                                                  3 months: 73±11 L\                                         3 months: 389±89 μm\                                             
                                                                                                                                                                                                                                                                                                                                                  (*P*=0.001)\                                               (*P*=0.001)\                                                     
                                                                                                                                                                                                                                                                                                                                                  6 months: 71±13 L\                                         6 months: 365±74 μm\                                             
                                                                                                                                                                                                                                                                                                                                                  (*P*=0.001)                                                (*P*=0.002)                                                      

  15 DEX                                                    From 60±10 L to 1 month: 73±10 L\         From 548±110 μm to 1 month: 357±69 μm\                                                                                                                                                                                                                                                                                                                                  
                                                            (*P*\<0.001)\                             (*P*\<0.001)\                                                                                                                                                                                                                                                                                                                                                           
                                                            3 months: 72±11 L\                        3 months: 391±102 μm\                                                                                                                                                                                                                                                                                                                                                   
                                                            (*P*\<0.001)\                             (*P*\<0.001)\                                                                                                                                                                                                                                                                                                                                                           
                                                            6 months: 66±13 L\                        6 months: 504±159 μm\                                                                                                                                                                                                                                                                                                                                                   
                                                            (*P*=0.009)\                              (*P*=0.05)\                                                                                                                                                                                                                                                                                                                                                             
                                                            1 month: *P*=0.86 vs DEX\                 1 month: *P*=0.92 vs DEX\                                                                                                                                                                                                                                                                                                                                               
                                                            3 months: *P*=0.80 vs DEX\                3 months: *P*=0.94 vs DEX\                                                                                                                                                                                                                                                                                                                                              
                                                            6 months: *P*=0.80 vs DEX                 6 months: *P*=0.01 vs DEX                                                                                                                                                                                                                                                                                                                                               

  EPISODIC 2 study[@b44-dddt-11-2359]                       Retrospective                             58 IGS of 100 overall                    NR                                                  1 DEX                                       24 months\   1.7 first year\                                                                       Baseline mean\                                             Baseline 518.13±117.2 μm\                                        6.2% IOP \>25 mmHg
                                                                                                                                                                                                                                               (25 eyes)    1.657 second year                                                                     58.5±15.6 L\                                               18 months: 346.9±115.7 μm\                                       
                                                                                                                                                                                                                                                                                                                                                  18 months: 66.9 (±18.3) L\                                 −176 μm (*P*\<0.001)\                                            
                                                                                                                                                                                                                                                                                                                                                  24 months: 62.3 L\                                         24 months: 340.2±116 μm\                                         
                                                                                                                                                                                                                                                                                                                                                  (±14.3)\                                                   −182.7 μm (*P*\<0.001)                                           
                                                                                                                                                                                                                                                                                                                                                  (*P*=0.0035)                                                                                                                

  Sacchi et al[@b45-dddt-11-2359]                           Case report                               1                                        Sub-Tenon's betamethasone                           1 DEX                                       6 months     NR                                                                                    From 20/40 to 1 month: 20/30                               NR                                                               IOP \>21 mmHg
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BCVA, best corrected visual acuity; CAIs, carbonic anhydrase inhibitors; CMT, central macular thickness; DEX, dexamethasone implant; ETDRS, Early Treatment Diabetic Retinopathy Study; IGS, Irvine-Gass syndrome; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; L, ETDRS letters; LE, left eye; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; RE, right eye; TA, triamcinolone acetonide; VAI, visual acuity improvement \>10 L; VEGF, vascular endothelial growth factor.

###### 

DEX in vasoproliferative retinal tumors

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                         Study design   No of eyes   Previous treatment       Treatment   Follow-up   Retreatment      BCVA                  CMT   Complications
  --------------------------------- -------------- ------------ ------------------------ ----------- ----------- ---------------- --------------------- ----- ------------------------
  Cebeci et al[@b48-dddt-11-2359]   Case report    3            IVT BEV\                 DEX         12 months   1 DEX + PDT\     From 20/25 to 20/40   NR    1 subcapsular cataract
                                                                Laser photocoagulation                           (1 week after)                               

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IVT, intravitreal; NR, not reported; PDT, photodynamic therapy.

###### 

Published studies on the use of DEX implant for retinal telangiectasia

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                          Study design    No of eyes   Previous treatment   Treatment   Follow-up   Retreatment   BCVA                                                                                                                                             CMT Complications
  ---------------------------------- --------------- ------------ -------------------- ----------- ----------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------
  Sandali et al[@b55-dddt-11-2359]   Case report     1            3 BEV IVT            DEX         15 months   2 DEX         From 20/32 to 1 month: 20/20                                                                                                                     From 398 μm NR to 1 month:\
                                                                                                                                                                                                                                                                              250 μm

  Loutfi et al[@b56-dddt-11-2359]    Case report     1            3 BEV IVT\           DEX         NR          3 DEX         From 0.3 to 0.59 logMAR: 6 weeks after 1st DEX; from 0.3 to 0.64 logMAR: 6 weeks after 2nd DEX; from 0.3 to 0.78 logMAR: 2 weeks after 3rd DEX   From 397 μm NR to 286 μm:\
                                                                  1 IVTA                                                                                                                                                                                                      6 weeks after 1° DEX; 6 weeks after 2° DEX:\
                                                                                                                                                                                                                                                                              279 μm; 2 weeks after 3° DEX:\
                                                                                                                                                                                                                                                                              279 μm

  Lei and Lam[@b62-dddt-11-2359]     Retrospective   1            8 ranibizumab\       DEX         17 months   4 DEX         From 1 to 52 weeks:\                                                                                                                             From 607 μm NR to 52 weeks: 346 μm
                                                                  IVT + laser                                                0.5 logMAR                                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; NR, not reported.

###### 

DEX implant in Coats' disease

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                    Study design                 No of eyes   Previous treatment                                    Primary treatment                                   Follow-up    Retreatment   BCVA                               CMT                               Complications
  -------------------------------------------- ---------------------------- ------------ ----------------------------------------------------- --------------------------------------------------- ------------ ------------- ---------------------------------- --------------------------------- ---------------------------------
  Saatci et al[@b60-dddt-11-2359]              Case report                  2            5 ranibizumab IVT + laser photocoagulation in 1 eye   DEX in one patient\                                 12 months\   NR            Unchanged\                         NR                                IOP rise \>25 mmHg in both eyes
                                                                                                                                               DEX + laser photocoagulation in the other patient   6 months                   From 2/10 to 3/10                                                    

  Martínez-Castillo et al[@b61-dddt-11-2359]   Case report                  1            None                                                  DEX + laser photocoagulation                        12 months    NR            From 20/200 to 20/25               NR                                None

  Lei and Lam[@b62-dddt-11-2359]               Retrospective chart review   1            3 BEV IVT + laser photocoagulation                    DEX                                                 16 months    3 DEX         From 1.3 to 52 weeks: 1.8 logMAR   From 821 μm to 52 weeks: 589 μm   None
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; NR, not reported.

###### 

Published studies on the use of DEX implant for radiation maculopathy

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                          Study design                No of eyes           Previous treatment                                                 Primary treatment                              Follow-up            Retreatment                  BCVA                                                                                         CMT                                                                              Complications
  ---------------------------------- --------------------------- -------------------- ------------------------------------------------------------------ ---------------------------------------------- -------------------- ---------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ---------------------
  Baillif et al[@b63-dddt-11-2359]   Retrospective               5                    None                                                               DEX                                            6.4 months           3 eyes: 1 DEX\               From 41 L to 2 months: 47 L                                                                  From 487.1 μm to 2 months: 331.2 μm                                              1 eye IOP \>25 mmHg
                                                                                                                                                                                                                             2 eyes: 2 DEX                                                                                                                                                                                              

  Caminal et al[@b64-dddt-11-2359]   Retrospective               12                   2 laser\                                                           DEX                                            8.2±7.8 months       1 eye: 2 DEX                 From 1±0.58 to 0.8±1.58\                                                                     From 416±263 to 254±170 μm\                                                      1 eye cataract\
                                                                                      2 VEGF IVT\                                                                                                                                                         logMAR\                                                                                      (*P*=0.016)                                                                      1 eye IOP rise
                                                                                      5 laser + anti-VEGF\                                                                                                                                                (*P*=0.091)                                                                                                                                                                   
                                                                                      IVT                                                                                                                                                                                                                                                                                                                                               

  Russo et al[@b65-dddt-11-2359]     Retrospective comparative   16                   NR                                                                 8 DEX                                          Range 7--52 months   2.4±0.9 DEX\                 DEX: from 0.45±0.18 to last follow-up: 0.27±0.15\                                            From 437±71 μm to last follow-up: 254±44 μm\                                     NR
                                                                                                                                                                                                                             (24 months)\                 logMAR\                                                                                      (*P*=0.012)                                                                      
                                                                                                                                                                                                                             (*P*=0.018 vs ranibizumab)   (*P*=0.011)                                                                                                                                                                   

  8 ranibizumab IVT                                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                 6±1.8 ranibizumab\   Ranibizumab: from 0.49±0.14 to last follow-up: 0.34±0.13 logMAR\   From 459±81 μm to last follow-up: 243±58 μm\                                                                                                                                                                                                                                   
                                                                 (24 months)          (*P*=0.012)                                                        (*P*=0.012) (*P*=0.721 vs ranibizumab)                                                                                                                                                                                                                                         

  Bui et al[@b66-dddt-11-2359]       Retrospective               2                    16 BEV IVT +4\                                                     DEX                                            NR                   2 DEX                        From 20/60 Snellen to 3 months: unchanged\                                                   From 456 to 238 μm after first DEX, 277 μm after second DEX From 618 to 336 μm   1 cataract surgery\
                                                                                      IVTA\                                                                                                                                                               From 20/400 Snellen to 3 months: unchanged                                                                                                                                    2 IOP rise
                                                                                      7 BEV +1 IVTA                                                                                                                                                                                                                                                                                                                                     

  Seibel et al[@b67-dddt-11-2359]    Retrospective comparative   5 DEX                None                                                               DEX                                            At least 12 months   1--2 DEX\                    DEX: 0.8 logMAR, unchanged\                                                                  DEX: from 440 μm to 4 weeks 265 μm\                                              NR
                                                                                                                                                                                                                             BEV (range 1--10)\           BEV: 0.8 logMAR, 1 month, after last IVT\                                                    (*P*=0.049\                                                                      
                                                                                                                                                                                                                             IVTA (range 1--3)            0.7 logMAR\                                                                                  BEV: from 479 μm to 4 weeks 362 μm (*P*=0.01)\                                   
                                                                                                                                                                                                                                                          IVTA: 0.8 logMAR, unchanged                                                                  IVTA: from 454 μm to 4 weeks 314 μm (*P*=0.034)                                  

  38 BEV                                                         BEV                                                                                                                                                                                                                                                                                                                                                                    

  35 IVTA                                                        IVTA                                                                                                                                                                                                                                                                                                                                                                   

  Tarmann et al[@b68-dddt-11-2359]   Retrospective               4                    BEV IVT in 3 eyes\                                                 DEX                                            NR                   NR                           From 20/100 Snellen to 2--4 weeks 20/50 to 10 weeks 20/80 Snellen to 14--17 weeks: 20/100\   From 616 μm to 2--4 weeks: 399 μm\                                               1 eye IOP \>25 mmHg
                                                                                      BEV IVT + panretinal laser photocoagulation and IVTA in 1 eye                                                                                                       Snellen                                                                                      10 weeks: 393 μm\                                                                
                                                                                                                                                                                                                                                                                                                                                       14--17 weeks: 568 μm                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BCVA, best corrected visual acuity; BEV, bevacizumab; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone acetonide; NR, not reported; VEGF, vascular endothelial growth factor.

###### 

DEX implant in retinitis pigmentosa

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                             Study design    No of eyes              Previous treatment                      Treatment   Follow-up   Retreatment                         BCVA                                          CMT                                                   Complications
  ------------------------------------- --------------- ----------------------- --------------------------------------- ----------- ----------- ----------------------------------- --------------------------------------------- ----------------------------------------------------- ---------------
  Srour et al[@b77-dddt-11-2359]        Retrospective   4                       CAIs in all cases subtenon TA 1 case\   DEX         6 months    2 DEX in 2 eyes after 3 months      From 20/160 to 6 months: 20/125 after 1 DEX   From 443±185 μm to 6 months: 305±124 μm after 1 DEX   None
                                                                                NSAIDs in 2 cases                                                                                                                                                                                       

  Ahn et al[@b78-dddt-11-2359]          Case report     2 eyes of one patient   CAIs\                                   DEX         12 months   2 DEX in 1 eye 6 months after DEX   From 20/100 to 12 months: 20/60 RE\           From 631 μm to 12 months: 531 μm RE\                  IOP rise\
                                                                                Anti-VEGF IVT                                                                                       From 20/150 to 12 months: 20/100 LE           From 681 μm to 12 months: 499 μm LE                   IOP\>21 mmHg

  Saatci et al[@b79-dddt-11-2359]       Case report     2 eyes of one patient   Topical CAIs                            1 DEX       7 months    NR                                  From 2/10 to 1 week: 4/10 both eyes\          NR                                                    None
                                                                                                                                                                                    3 months: 2/10 both eyes                                                                            

  Patil and Lotery[@b80-dddt-11-2359]   Case report     1                       Topical CAIs\                           1 DEX       10 months   NR                                  From 1.01 logMAR to 6 weeks: 0.89 logMAR      From 559 μm to 6 weeks: 271 μm                        None
                                                                                Depo-Medrone Parabulbar\                                                                                                                                                                                
                                                                                Anti-VEGF IVT\                                                                                                                                                                                          
                                                                                IVTA\                                                                                                                                                                                                   
                                                                                Cryotherapy                                                                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BCVA, best corrected visual acuity; CAIs, carbonic anhydrase inhibitors; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone; LE, left eye; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; RE, right eye; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.

###### 

Published studies on the use of DEX implant for other conditions

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                   Study design    No of eyes                                                      Previous treatment                          Primary treatment   Follow-up         Retreatment        BCVA                                                             CMT                                                                                 Complications
  ------------------------------------------- --------------- --------------------------------------------------------------- ------------------------------------------- ------------------- ----------------- ------------------ ---------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------
  Furino et al[@b81-dddt-11-2359]             Retrospective   8 PPV + ILM peeling + cataract surgery                          Diclofenac sodium and betamethasone drops   DEX                 6.75±0.71 month   NR                 From 20/50 to 20/23\                                             From 438±45 μm to 296±49 μm\                                                        No eye IOP \>18 mmHg
                                                                                                                                                                                                                                   *P*\<0.00001                                                     *P*\<0.00001                                                                        

  Taney et al[@b82-dddt-11-2359]              Retrospective   5 PPV with ERM peeling                                          Topical prednisolone 1%\                    DEX                 NR                1 DEX in 3 eyes\   3 Snellen lines improvement in 3 eyes at 4--6 weeks after DEX\   Mean CMT decrease of 106 μm (range 56--155 μm) in 4 eyes at 4--6 weeks after DEX\   1 eye IOP \>25 mmHg\
                                                                                                                              Topical NSAIDs\                                                                   9 DEX in 1 eye\    1 Snellen line improvement in 1 eye at 4--6 weeks after DEX\     No CMT improvement in 1 eye at 4--6 weeks after DEX                                 Cataract in 1 out of the 2 phakic eyes
                                                                                                                              Subtenon TA IVTA in 1 eye\                                                        7 DEX in 1 eye     No BCVA improvement in 1 eye at 4--6 weeks after DEX                                                                                                 
                                                                                                                              Anti-VEGF IVT in 3 eyes\                                                                                                                                                                                                                                  
                                                                                                                              Anti-VEGF IVT 1 eye                                                                                                                                                                                                                                       

  Merkoudis and Granstam[@b83-dddt-11-2359]   Case report     1 PPV + ILM peeling and C~2~F~6~ tamponade + cataract surgery   IVTA\                                       1 DEX               10 months         NR                 From 20/200 to 2 months: 20/40                                   Reduction of CMT 2 months after DEX                                                 None
                                                                                                                              Topical NSAIDs\                                                                                                                                                                                                                                           
                                                                                                                              Oral CAI\                                                                                                                                                                                                                                                 
                                                                                                                              Anti-VEGF IVT                                                                                                                                                                                                                                             

  Georgalas et al[@b84-dddt-11-2359]          Case report     1 PPV + ILM peeling cataract surgery                            Topical steroids\                           1 DEX               6 months          NR                 From counting fingers to 1 week: 6/36                            From 640 μm to 1 week: 383 μm                                                       None
                                                                                                                              Subtenon steroids\                                                                                                                                                                                                                                        
                                                                                                                              Intravitreal steroids                                                                                                                                                                                                                                     

  Bonfiglio et al[@b85-dddt-11-2359]          Case report     1 scleral buckling + cryopexy                                   Oral prednisolone\                          1 DEX               6 months          NR                 From 0.70 to 6 months: 0.20\                                     From 510 μm to 6 months: 290 μm                                                     None
                                                                                                                              Oral CAI\                                                                                            logMAR                                                                                                                                               
                                                                                                                              Topical prednisolone\                                                                                                                                                                                                                                     
                                                                                                                              Topical NSAIDs\                                                                                                                                                                                                                                           
                                                                                                                              TA Subtenon                                                                                                                                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BCVA, best corrected visual acuity; CAI, carbonic anhydrase inhibitor; CMT, central macular thickness; DEX, dexamethasone implant; ERM, epiretinal membrane; ILM, inner limiting membrane; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; PPV, pars plana vitrectomy; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.
